3 May 2017

Holding(s) in Company

RNS Number : 1162E
Verona Pharma PLC
03 May 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Verona Pharma plc  

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):



3. Full name of person(s) subject to the
notification obligation:
iii

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:

 

HSBC Global Custody Nominee (UK) Limited  501,275*                                                              

 

Chase (GA Group) Nominees Limited        1,292,033*

 

State Street Nominees Limited                         63,903*

 

Available on request                                          2,482*

                                        

*denotes direct interest

 

Chase (GA Group) Nominees Limited            233,235

 

Chase Nominees Limited                                     62,166

 

Vidacos Nominees Limited                                323,354

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

28 April 2017

6. Date on which issuer notified:

2 May 2017

7. Threshold(s) that is/are crossed or
reached:
vi, vii

5% to 3% Change at Direct Interest Level (Box 8A) & 7% to <5% Change at Combined Interest Level (Box 8A)

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares


GB00B06GSH43

181,042,592

181,042,592

2,478,448

1,859,693

618,755

3.62%

1.20%


 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

RIGHT TO RECALL LOANED SHARES

 

N/A

N/A

800,000*

 

*Direct Interest

1.56%

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 






Nominal

Delta



 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,278,448

6.38%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited and Friends Provident International Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

Friends Provident International Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·    Friends Provident International Limited (wholly owned subsidiary of Aviva Group Holdings Limited)


Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:


 

 


13. Additional information:

Figures are based on a total number of voting rights of 51,361,064, as per the Company's Total Voting Rights and Block Listing Interim Review Announcement of 13 February 2017.

14. Contact name:

     Neil Whittaker, Aviva plc

15. Contact telephone number:

     01603 684420

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBAAUPMGQW

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us